Sorry, you need to enable JavaScript to visit this website.

So far – So good!

You appear to meet the basic requirements for this Renoir vaccine study. Please enter your information below to find a study location near you. By doing so, you also opt-in to be contacted about future Pfizer studies. Once you select a site, the research study staff will contact you to see if you qualify to enroll.

Hasta aquí, todo bien...

Parece que su hijo cumple los requisitos básicos para este estudio de la vacuna contra la COVID-19. Sin embargo, solo el personal del estudio de investigación podrá determinar completamente si su hijo reúne los requisitos para inscribirse. Introduzca su información de contacto y seleccione “Encontrar un centro” para ver si hay un centro del estudio inscribiendo participantes en su zona.

Nota: Los padres de familia y tutores deben introducir su información de contacto, no la de su hijo.

Sorry, you are not eligible at this time...

Thank you so much for your interest in the Renoir vaccine study and for answering our questions.

There may be other research studies enrolling in your area in the future. Please consider entering your information below if you would like to be contacted about future clinical research opportunities.

Lo sentimos, su hijo no es elegible en este momento...

Gracias por su interés en este estudio de la vacuna contra la COVID-19 y por responder nuestras preguntas. Comuníquese con su proveedor de atención médica si tiene alguna pregunta médica. Además, considere ingresar su información a continuación para que se comuniquen con usted acerca de las oportunidades de estudios de investigación futuros.

Help Us in the Fight Against RSV

Introducing a research study for an investigational respiratory syncytial virus vaccine for people 60 years of age and older.


Question 1 of 3

Are you 60 years old or older?

Question 2 of 3

Are you currently able to complete most daily activities with no more than minimal assistance?

Question 3 of 3

Do you have a chronic medical condition that has required a change in therapy or hospitalization over the past 2 months?

Please select a full valid address.

Choose a Location

See below to select a research site near you. If you don’t see a site near you, then select "The sites listed here are not convenient for me." Study locations are being added regularly. A study representative will call you if a research site becomes available in your area.

The sites listed here are not convenient for me.

Pfizer RSV Vaccine Study

About the Study

Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in adults (second to the flu) with no effective treatment or prevention options. Usually, RSV symptoms in healthy adults are mild and can feel like a cold. However, sometimes RSV can be more serious, especially in babies, older adults, and those with heart or lung problems or weakened immune systems. Severe RSV can cause problems like pneumonia (an infection of the lungs). It can also worsen symptoms for people who have chronic obstructive pulmonary disease (COPD) or congestive heart failure (CHF).

Around the world, there is an urgent need for a vaccine that can prevent RSV in older adults. That’s why Pfizer is working to develop an RSV vaccine.

Like the flu season, RSV season usually happens between late fall and early spring, lasting approximately six to nine months depending on the region or country. This study will be conducted over the course of three RSV seasons. There is usually one RSV season per year, so participants could be in this study for about three years.

Who Can Participate

This study is enrolling people who:

  • Are 60 years and older
  • Are generally healthy or have stable chronic conditions
  • Do not have a history of severe side effects from or allergic reactions to vaccines

There will be other study requirements that the study team will discuss with you.


An Important Contribution

Joining a clinical trial is an important and personal decision. Your participation in this research study can help advance an investigational RSV vaccine for people who are 60 years and older. So, thank you for taking the time to learn more.

Header Image

What to Expect


If you meet all the study criteria for participation, you will receive the study vaccine (investigational or placebo) at your first study visit. The placebo looks like the investigational vaccine but does not contain any active ingredients. You have an equal chance of receiving either the investigational vaccine or the placebo. Neither you nor the study team will know which vaccine you receive.


About one month after you receive the study vaccine and then again at the end of the first RSV season, you will have a follow-up visit with the study team. After that, you will have one study visit at the beginning and one study visit at the end of each of the next two RSV seasons. There will be approximately seven study visits altogether and some may take place over the phone.


The study team will monitor any side effects and/or symptoms you may be experiencing. They will check in with you during study visits and will review your required weekly electronic diary (eDiary) entries about your health. If you have respiratory symptoms during the RSV season, you will be asked to collect and send a nasal swab to the study team for testing.

Keep in mind that you are free to stop being in this study at any time and for any reason.


The study vaccine and any study-related procedures are generally covered at no cost. You will also be reimbursed for any reasonable expenses you have as a result of taking part in this study. This may include parking, meals, or other travel-related expenses.

Header Image